Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.

Lancet

Volumn 361, Issue 9352, 2003, Pages

  Brittenham, G M ^a   Nathan, D G ^a   Olivieri, N F ^a   Pippard, M J ^a   Weatherall, D J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

BETA THALASSEMIA; CARDIOMYOPATHY; HUMAN; MORTALITY; NOTE; REPRODUCIBILITY;

BETA-THALASSEMIA; CARDIOMYOPATHIES; DEFEROXAMINE; HUMANS; IRON CHELATING AGENTS; PYRIDONES; REPRODUCIBILITY OF RESULTS;

MLCS; MLOWN;

EID: 0037431884     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(03)12223-4     Document Type: Note

References (0)